Harvard Bioscience (NASDAQ:HBIO) Share Price Crosses Below 200-Day Moving Average of $4.49

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $4.49 and traded as low as $4.26. Harvard Bioscience shares last traded at $4.36, with a volume of 53,829 shares traded.

Harvard Bioscience Price Performance

The company has a current ratio of 1.85, a quick ratio of 0.92 and a debt-to-equity ratio of 0.42. The company has a market cap of $189.22 million, a PE ratio of -54.49 and a beta of 1.43. The firm has a 50 day moving average of $4.47 and a two-hundred day moving average of $4.49.

Hedge Funds Weigh In On Harvard Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in shares of Harvard Bioscience by 7.3% during the 1st quarter. Bank of New York Mellon Corp now owns 266,314 shares of the medical instruments supplier’s stock valued at $1,653,000 after buying an additional 18,169 shares during the period. Rhumbline Advisers raised its holdings in Harvard Bioscience by 46.7% during the first quarter. Rhumbline Advisers now owns 36,190 shares of the medical instruments supplier’s stock valued at $225,000 after acquiring an additional 11,518 shares during the period. Vanguard Group Inc. raised its holdings in Harvard Bioscience by 12.8% during the first quarter. Vanguard Group Inc. now owns 1,924,517 shares of the medical instruments supplier’s stock valued at $11,952,000 after acquiring an additional 218,832 shares during the period. Lazard Asset Management LLC raised its holdings in Harvard Bioscience by 230.5% during the first quarter. Lazard Asset Management LLC now owns 7,120 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 4,966 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Harvard Bioscience by 26.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 266,192 shares of the medical instruments supplier’s stock worth $1,654,000 after purchasing an additional 56,321 shares during the last quarter. 76.06% of the stock is owned by institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.